Lever, Elliott;
Colquhoun, Matthew;
Flora, Kalveer;
El-Ghazali, Shawki;
Baslas, Rohit;
Suleman, Yasir;
Wieckowski, Amy;
... Machado, Pedro M; + view all
(2022)
Rituximab in rheumatology: single-centre SARS-CoV-2 infection and COVID-19 prevalence.
Rheumatology Advances in Practice
, 6
(1)
, Article rkac009. 10.1093/rap/rkac009.
Preview |
Text
rkac009.pdf - Published Version Download (137kB) | Preview |
Abstract
We describe a coronavirus disease 2019 (COVID-19) prevalence of 20% in rheumatic disease patients treated with rituximab, with 10.3% of these (2% of the entire cohort) having died of COVID-19-related causes.
Type: | Article |
---|---|
Title: | Rituximab in rheumatology: single-centre SARS-CoV-2 infection and COVID-19 prevalence. |
Location: | England |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1093/rap/rkac009 |
Publisher version: | https://doi.org/10.1093/rap/rkac009 |
Language: | English |
Additional information: | © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Department of Neuromuscular Diseases UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology |
URI: | https://discovery.ucl.ac.uk/id/eprint/10146639 |
Archive Staff Only
![]() |
View Item |